Bridged nucleic acids reloaded

Autores
Soler Bistue, Alfonso J. C.; Zorreguieta, Ángeles; Tolmasky, Marcelo E.
Año de publicación
2019
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Oligonucleotides are key compounds widely used for research, diagnostics, and therapeutics. The rapid increase in oligonucleotide-based applications, together with the progress in nucleic acids research, has led to the design of nucleotide analogs that, when part of these oligomers, enhance their efficiency, bioavailability, or stability. One of the most useful nucleotide analogs is the first-generation bridged nucleic acids (BNA), also known as locked nucleic acids (LNA), which were used in combination with ribonucleotides, deoxyribonucleotides, or other analogs to construct oligomers with diverse applications. However, there is still room to improve their efficiency, bioavailability, stability, and, importantly, toxicity. A second-generation BNA, BNANC (20 -O,40 -aminoethylene bridged nucleic acid), has been recently made available. Oligomers containing these analogs not only showed less toxicity when compared to LNA-containing compounds but, in some cases, also exhibited higher specificity. Although there are still few applications where BNANC-containing compounds have been researched, the promising results warrant more effort in incorporating these analogs for other applications. Furthermore, newer BNA compounds will be introduced in the near future, offering great hope to oligonucleotide-based fields of research and applications.
Fil: Soler Bistue, Alfonso J. C.. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas. - Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Biotecnológicas; Argentina
Fil: Zorreguieta, Ángeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina
Fil: Tolmasky, Marcelo E.. California State University; Estados Unidos
Materia
ANTIBIOTIC RESISTANCE
ANTISENSE
BRIDGED NUCLEIC ACIDS
CAS9
CRISPR
HEMATOLOGIC MALIGNANCIES
HYPERCHOLESTEROLEMIA
LOCKED NUCLEIC ACIDS
MYOTONIC DYSTROPHY
OLIGONUCLEOTIDES
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/151385

id CONICETDig_ca278490f124df8367587d5b4d95615d
oai_identifier_str oai:ri.conicet.gov.ar:11336/151385
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Bridged nucleic acids reloadedSoler Bistue, Alfonso J. C.Zorreguieta, ÁngelesTolmasky, Marcelo E.ANTIBIOTIC RESISTANCEANTISENSEBRIDGED NUCLEIC ACIDSCAS9CRISPRHEMATOLOGIC MALIGNANCIESHYPERCHOLESTEROLEMIALOCKED NUCLEIC ACIDSMYOTONIC DYSTROPHYOLIGONUCLEOTIDEShttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Oligonucleotides are key compounds widely used for research, diagnostics, and therapeutics. The rapid increase in oligonucleotide-based applications, together with the progress in nucleic acids research, has led to the design of nucleotide analogs that, when part of these oligomers, enhance their efficiency, bioavailability, or stability. One of the most useful nucleotide analogs is the first-generation bridged nucleic acids (BNA), also known as locked nucleic acids (LNA), which were used in combination with ribonucleotides, deoxyribonucleotides, or other analogs to construct oligomers with diverse applications. However, there is still room to improve their efficiency, bioavailability, stability, and, importantly, toxicity. A second-generation BNA, BNANC (20 -O,40 -aminoethylene bridged nucleic acid), has been recently made available. Oligomers containing these analogs not only showed less toxicity when compared to LNA-containing compounds but, in some cases, also exhibited higher specificity. Although there are still few applications where BNANC-containing compounds have been researched, the promising results warrant more effort in incorporating these analogs for other applications. Furthermore, newer BNA compounds will be introduced in the near future, offering great hope to oligonucleotide-based fields of research and applications.Fil: Soler Bistue, Alfonso J. C.. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas. - Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Biotecnológicas; ArgentinaFil: Zorreguieta, Ángeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; ArgentinaFil: Tolmasky, Marcelo E.. California State University; Estados UnidosMolecular Diversity Preservation International2019-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/151385Soler Bistue, Alfonso J. C.; Zorreguieta, Ángeles; Tolmasky, Marcelo E.; Bridged nucleic acids reloaded; Molecular Diversity Preservation International; Molecules; 24; 12; 6-2019; 1-171420-3049CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1420-3049/24/12/2297info:eu-repo/semantics/altIdentifier/doi/10.3390/molecules24122297info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:37:29Zoai:ri.conicet.gov.ar:11336/151385instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:37:29.689CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Bridged nucleic acids reloaded
title Bridged nucleic acids reloaded
spellingShingle Bridged nucleic acids reloaded
Soler Bistue, Alfonso J. C.
ANTIBIOTIC RESISTANCE
ANTISENSE
BRIDGED NUCLEIC ACIDS
CAS9
CRISPR
HEMATOLOGIC MALIGNANCIES
HYPERCHOLESTEROLEMIA
LOCKED NUCLEIC ACIDS
MYOTONIC DYSTROPHY
OLIGONUCLEOTIDES
title_short Bridged nucleic acids reloaded
title_full Bridged nucleic acids reloaded
title_fullStr Bridged nucleic acids reloaded
title_full_unstemmed Bridged nucleic acids reloaded
title_sort Bridged nucleic acids reloaded
dc.creator.none.fl_str_mv Soler Bistue, Alfonso J. C.
Zorreguieta, Ángeles
Tolmasky, Marcelo E.
author Soler Bistue, Alfonso J. C.
author_facet Soler Bistue, Alfonso J. C.
Zorreguieta, Ángeles
Tolmasky, Marcelo E.
author_role author
author2 Zorreguieta, Ángeles
Tolmasky, Marcelo E.
author2_role author
author
dc.subject.none.fl_str_mv ANTIBIOTIC RESISTANCE
ANTISENSE
BRIDGED NUCLEIC ACIDS
CAS9
CRISPR
HEMATOLOGIC MALIGNANCIES
HYPERCHOLESTEROLEMIA
LOCKED NUCLEIC ACIDS
MYOTONIC DYSTROPHY
OLIGONUCLEOTIDES
topic ANTIBIOTIC RESISTANCE
ANTISENSE
BRIDGED NUCLEIC ACIDS
CAS9
CRISPR
HEMATOLOGIC MALIGNANCIES
HYPERCHOLESTEROLEMIA
LOCKED NUCLEIC ACIDS
MYOTONIC DYSTROPHY
OLIGONUCLEOTIDES
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Oligonucleotides are key compounds widely used for research, diagnostics, and therapeutics. The rapid increase in oligonucleotide-based applications, together with the progress in nucleic acids research, has led to the design of nucleotide analogs that, when part of these oligomers, enhance their efficiency, bioavailability, or stability. One of the most useful nucleotide analogs is the first-generation bridged nucleic acids (BNA), also known as locked nucleic acids (LNA), which were used in combination with ribonucleotides, deoxyribonucleotides, or other analogs to construct oligomers with diverse applications. However, there is still room to improve their efficiency, bioavailability, stability, and, importantly, toxicity. A second-generation BNA, BNANC (20 -O,40 -aminoethylene bridged nucleic acid), has been recently made available. Oligomers containing these analogs not only showed less toxicity when compared to LNA-containing compounds but, in some cases, also exhibited higher specificity. Although there are still few applications where BNANC-containing compounds have been researched, the promising results warrant more effort in incorporating these analogs for other applications. Furthermore, newer BNA compounds will be introduced in the near future, offering great hope to oligonucleotide-based fields of research and applications.
Fil: Soler Bistue, Alfonso J. C.. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas. - Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Biotecnológicas; Argentina
Fil: Zorreguieta, Ángeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina
Fil: Tolmasky, Marcelo E.. California State University; Estados Unidos
description Oligonucleotides are key compounds widely used for research, diagnostics, and therapeutics. The rapid increase in oligonucleotide-based applications, together with the progress in nucleic acids research, has led to the design of nucleotide analogs that, when part of these oligomers, enhance their efficiency, bioavailability, or stability. One of the most useful nucleotide analogs is the first-generation bridged nucleic acids (BNA), also known as locked nucleic acids (LNA), which were used in combination with ribonucleotides, deoxyribonucleotides, or other analogs to construct oligomers with diverse applications. However, there is still room to improve their efficiency, bioavailability, stability, and, importantly, toxicity. A second-generation BNA, BNANC (20 -O,40 -aminoethylene bridged nucleic acid), has been recently made available. Oligomers containing these analogs not only showed less toxicity when compared to LNA-containing compounds but, in some cases, also exhibited higher specificity. Although there are still few applications where BNANC-containing compounds have been researched, the promising results warrant more effort in incorporating these analogs for other applications. Furthermore, newer BNA compounds will be introduced in the near future, offering great hope to oligonucleotide-based fields of research and applications.
publishDate 2019
dc.date.none.fl_str_mv 2019-06
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/151385
Soler Bistue, Alfonso J. C.; Zorreguieta, Ángeles; Tolmasky, Marcelo E.; Bridged nucleic acids reloaded; Molecular Diversity Preservation International; Molecules; 24; 12; 6-2019; 1-17
1420-3049
CONICET Digital
CONICET
url http://hdl.handle.net/11336/151385
identifier_str_mv Soler Bistue, Alfonso J. C.; Zorreguieta, Ángeles; Tolmasky, Marcelo E.; Bridged nucleic acids reloaded; Molecular Diversity Preservation International; Molecules; 24; 12; 6-2019; 1-17
1420-3049
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1420-3049/24/12/2297
info:eu-repo/semantics/altIdentifier/doi/10.3390/molecules24122297
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Molecular Diversity Preservation International
publisher.none.fl_str_mv Molecular Diversity Preservation International
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613180868788224
score 13.070432